Background: Many patients are diagnosed with cancer through the emergency pathway; a route which is associated with inferior outcomes and increased costs to the patient and healthcare system. Lung cancer constitutes the largest proportion of emergency presentations (EP). Small cell lung cancer (SCLC), which represents only 10-15% of all lung cancers, constitutes a disproportionate amount of presentations via the emergency route. Methods: Data was collected retrospectively from four non-teaching hospitals in the United Kingdom over the period of January to December 2016. Only patients with histological confirmation of SCLC were included. We compared the EP population with the population who presented electively in the following categories: -demographicsperformance status -stage at presentation of disease -proportion who proceeded to have chemotherapy -the survival data for this group of patients. Results: 80 patients were identified across four hospitals. 33% (n ¼ 27) presented via the EP route, while 67% (n ¼ 53) presented via the elective referral route. The demographics of the two sub-groups are comparable, although there is a higher proportion of patients with extensive disease in the EP group (88% vs 69.8%). While the proportion who received systemic treatment was only marginally higher in the elective referral route (66% vs 55%), there was a substantial difference in overall survival. The divergence in the Kaplan-Meier curves occur most markedly within the first 30-days. Conclusions: 1. A disproportionately high number of SCLC present via the Emergency Pathway, which is predictable due to its rapidly progressing nature. 2. Apart from the extent of disease, the demographics between both sub-groups are comparable, including performance status and even proportion who received systemic treatment. 3. There is a substantial difference in overall survival between the two subgroups, with divergence especially within the first month after diagnosis in their Kaplan-Meier curves. Background: Amrubicin is one of the most active chemotherapeutic agents for smallcell lung cancer (SCLC). Previous studies reported its effectiveness and severe hematological toxicity. However, the efficacy of amrubicin monotherapy in elderly patients with SCLC has not been described. The objective of this study was to investigate the feasibility of amrubicin monotherapy in elderly patients, and its efficacy for relapsed SCLC. Methods: A retrospective cohort study design was used. We retrospectively evaluated the clinical effects and adverse events of amrubicin treatment in elderly (!70 years) SCLC patients with relapsed SCLC. Results: Between November 2003 and September 2015, 86 patients (aged !70 years) received amrubicin monotherapy for relapsed SCLC at four institutions. There were 42 cases of sensitive relapse (S) and 44 of refractory relapse (R). S cases with median age of 75 years (range, 70-85 years) and R cases with median age of 74 years (range, 70-84 years) were included in our analysis. The median number of treatment cycles was 3 (range 1-9), and the response rate was 33.7% (40.5% in the S and 27.2% in the R cases). Median progression-free survival time was 4.0 months in the S and 2.7 months in the R patients (p ¼ 0.013). Median survival time from the start of amrubicin therapy was 7.6 months in the S and 5.5 months in the R cases (p ¼ 0.26). The frequencies of grade !3 hematological toxicities were as follows: leukopenia, 60.4%; neutropenia, 74.4%; anemia, 11.6%; thrombocytopenia, 16.2%; and febrile neutropenia, 17.4%. Treatmentrelated death was observed in 1 patient. Conclusions: Although hematological toxicities, particularly neutropenia, were severe, amrubicin showed excellent anti-tumor activity, not only in the S, but also in the R cases, as shown in previous studies. Amrubicin could be a preferable standard treatment in elderly patients with relapsed SCLC. These results warrant further evaluation of amrubicin in elderly patients with relapsed SCLC by a prospective trial. Legal entity responsible for the study: N/A. Background: Patients with epidermal growth factor receptor (EGFR) mutant advanced non-small cell lung cancer (NSCLC) developed resistance to first-or second-generation EGFR-tyrosine kinase inhibitor (TKI) after 9-13 months and third-generation EGFR-TKI after 10 months, respectively. Small cell lung cancer (SCLC) transformation is a rare resistance mechanism in these patients. Methods: Tissue re-biopsy in 35 patients with EGFR mutant advanced NSCLC who failed first-line EGFR-TKI; and 4 patients with acquired T790M mutant advanced NSCLC who failed third-generation EGFR-TKI, to look for SCLC transformation. Results: SCLC transformation was identified in 2 out of 35 (5.7%) patients who failed first-line EGFR-TKI and 1 out of 4 (25.0%) patients who failed third-generation EGFR-TKI. All 3 patients were never smoker. The first patient was a 70-year-old male with exon 19 deletion stage IV lung adenocarcinoma. He had partial response (PR) to gefitinib 250 mg daily but developed symptomatic progressive disease (PD) after 26 months. Re-biopsy of his enlarging primary lung lesion showed SCLC transformation. The second patient was a 43-year-old male with exon 19 deletion stage IV lung adenocarcinoma. He had PR to gefitinib 250 mg daily but developed symptomatic PD after 15 months. Re-biopsy of his enlarging primary lung lesion showed SCLC transformation and plasma was positive for T790M mutation. The third patient was a 62-year-old female with exon 21 L858R stage IV lung adenocarcinoma. She had PR to gefitinib 250 mg daily but experienced symptomatic PD after 8 months' of gefitinib therapy. Re- Internal Medicine, Gyeongsang National University Changwon Hospital, Changwon, Republic of Korea Background: The importance of nutritional status and chronic inflammation has been emphasized in cancer. We investigated the impact of the Onodera's prognostic nutritional index (PNI) on clinical outcomes in patients with small cell lung cancer (SCLC). Methods: Data of 220 SCLC patients treated with first-line platinum-based chemotherapy from 2006 to 2017 were retrospectively reviewed. The PNI was calculated as 10 Â serum albumin (g/dL) þ 0.005 Â absolute lymphocyte count (/mm 3 ). Those with the PNI > 45, 40 -45, and < 40 were categorized as high, intermediate, and low PNI groups, respectively. Results: The proportion of non-responders to first-line therapy was significantly increased as the PNI was decreased (high, intermediate, and low PNI group, 6.7%, 18.0%, and 30.8%, p < 0.001). Early discontinuation of first-line therapy due to treatment related toxicity occurred more frequently in lower PNI group (high, intermediate, and low PNI group, 5.8%, 21.3%, and 25.6%, p < 0.001). The 1-year progression-free survival (PFS) and overall survival (OS) rates were 29% and 61%, 19% and 46%, and 3% and 23% in high, intermediate, and low PNI group, respectively. On multivariate analyses, the low PNI group was independently associated with poor PFS (HR ¼ 1.592, 95% CI ¼ 1.009 -2.511, p ¼ 0.046) and OS (HR ¼ 1.911, 95% CI ¼ 1.208 -3.024, p ¼ 0.006) compared with the high PNI group. Conclusions: SCLC patients with the PNI < 40 showed low treatment response rate, intolerance to chemotherapy, and poor prognosis. Further evaluation is needed to validate this findings. Background: The number of available regimens which can be used in relapsed smallcell lung cancer (SCLC) is small and the data of the regimens is lack than those of nonsmall cell lung cancer. The goal of the present study is to evaluate the clinical outcome of ifosfamide and carboplatin (IC) regimen for third-or further-line chemotherapy in SCLC patients. Methods: A retrospective analysis was conducted of all patients who received combination chemotherapy with IC regimenbetween 2011 and 2015 for SCLC. The data included baseline demographics, chemotherapy-related toxicities, therapeutic regimens that used and survival period.
Results: A total of 12 patients were administered IC regimen. All of the IC regimens were used in third-or further-line chemotherapy and 9 (75%) of cases were fourth-line therapy. Of the 37 chemotherapy-related toxicity events, 27 (73%) were hematologic toxicities and thrombocytopenia (n ¼ 10 (27%)) was reported most frequently. The median overall survival (OS) after IC administration was 3.5 months. Patients with positive change of body mass index (BMI) before IC administration (p ¼ 0.071), without multiple metastases at start of IC regimen (p ¼ 0.001), refractory relapse after first line treatment (p ¼ 0.082), partial response or stable disease to the IC treatment (p ¼ 0.007) showed longer duration of OS. 
